CELLIVITY is available to adults only. Supplement pages are general product information; peptide records are not a sales offer and are not for human use.
Age confirmation is a declaration, not identity verification. Restricted research access still requires separate professional eligibility checks.Privacy and legal notice ↗
Open full-size image ↗Packaging concept; the selected format is shown below.Selected format: 500 mg
This image is a CELLIVITY packaging concept. Current stock arrived in clear vials without individual labels; product details are on the outer box of 10 vials. Packaging for your selected quantity will be confirmed when you enquire.
CELLIVITY PEPTIDE LABS · CEL-R-NAD-001
NAD+
Coenzyme research material; not a peptide
For laboratory research only · Not intended for human or veterinary use.
THAILAND LAUNCH PRICE฿2,500500 mg · per vial · tax and delivery confirmed at enquiry
Received · batch documentation under reviewAvailability is confirmed for this exact format before any commitment.
NAD+ is a nucleotide-derived coenzyme central to redox reactions and cellular energy transfer; it is not a peptide. Measuring or modifying NAD-related pathways is biologically interesting, but a vial presentation does not by itself demonstrate a clinical longevity benefit.
Research focus
Nicotinamide adenine dinucleotide biology and analytical research.
Current evidence context
Mechanistic importance is not proof that a parenteral NAD+ product improves healthspan or lifespan. Formulation, route, exposure and clinical outcomes require separate evidence.
Questions this record follows
How do tissue and blood NAD-related measurements relate to meaningful outcomes?
How stable is NAD+ across formulation, transport and storage conditions?
Which controlled human endpoints distinguish biomarker change from clinical benefit?
Follow the sources
Registry entries identify reference substances. Literature links describe research and do not certify this product or its batch.
Exact CELLIVITY-batch review is pending. Reference files below describe their own declared samples.
Reference clarification required
The PepNexa HPLC plot and table disagree on retention time and peak areas. The mass spectrum and structure sheet also need clarification. Original instrument files and corrected, linked documents are needed before these references can qualify a batch.
Purity, identity, per-vial content and sterility are separate results.
Request current availability for a lawful institutional, analytical or laboratory purpose. We confirm the exact presentation, price, batch and document state before any next step.
Exact presentation review
Jurisdiction and purpose check
Batch-document confirmation
No medical or human-use guidance
SELECTED PRODUCTNAD+CEL-R-NAD-001 · response after manual review
NAD+: before you enquire
What exactly does the selected format mean?＋
The mg or IU value is the declared material content per vial; it is not the container volume. Your selected presentation and quantity are saved with your enquiry. The final price is confirmed in the response.
Which batch will be supplied?＋
The specific batch and its documents are confirmed in the response. Files shown here may be supplier reference samples; the current record does not yet contain a qualified CELLIVITY lot dossier.
When can it arrive in Thailand?＋
For confirmed local stock, the planned window is 2–3 working days in Thailand. Pattaya timing is agreed directly. Incoming or specially sourced products have a separate estimate, confirmed before a commitment.
Can I enquire about several products together?＋
Yes. Add each format and quantity to the cart, then send one availability enquiry. Your selected items are kept together for review.
CELLIVITY
NAD+
CEL-R-NAD-001 · 500 mg
NAD+ is a nucleotide-derived coenzyme central to redox reactions and cellular energy transfer; it is not a peptide. Measuring or modifying NAD-related pathways is biologically interesting, but a vial presentation does not by itself demonstrate a clinical longevity benefit.
Nicotinamide adenine dinucleotide biology and analytical research.
Mechanistic importance is not proof that a parenteral NAD+ product improves healthspan or lifespan. Formulation, route, exposure and clinical outcomes require separate evidence.
How do tissue and blood NAD-related measurements relate to meaningful outcomes?
How stable is NAD+ across formulation, transport and storage conditions?
Which controlled human endpoints distinguish biomarker change from clinical benefit?
